Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Patients—The Relationship with Platelets Indicators DOI Creative Commons
Danusia Onișor, Andrada Larisa Roiban, Simona Cernea

и другие.

Medicina, Год журнала: 2024, Номер 60(12), С. 2091 - 2091

Опубликована: Дек. 21, 2024

Background and Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important chronic with major health risks, especially in the presence of T2DM, but pathophysiology this condition not fully understood. This study aimed to investigate platelet hematometric indices patients T2DM MASLD. Materials Methods: Demographic medical (including anthropometric) data were collected from 271 participants, whom blood samples also drawn fasting conditions for complete count, metabolic panel, ferritin, haptoglobin, creatinine, fibrosis markers. The correlations main parameters clinical laboratory investigated by bivariate multiple regression analyses. Results: median platelets number was 235·103/μL, thus, population divided into two subgroups: higher lower numbers (group 1 (mean): 286.38 ± 43.29·103/μL group 2 188.12 39.77·103/μL). Despite similar BMIs, had fatty index (FLI) (84.44 18.04 vs. 79.85 17.98; p = 0.0088) insulin resistance (HOMA-IR: 3.16 1.50 2.63 1.31; 0.0008), direct bilirubin, transaminases, uric acid, ferritin concentrations. Higher percentages males subjects HOMA-IR values >2.5 accounted group. In analyses, count plateletcrit (PTC) correlated independently sex, leucocyte HOMA-IR, bilirubin concentrations (p < 0.0001). distribution width (PDW) positively separate analyses (β 0.060; 0.0004, β 0.052; 0.0025), GGT, while mean volume presented a weak significant positive association FLI. Patients PDW PTC. Conclusions: Male MASLD PTC larger PDW. associated

Язык: Английский

Hot and Cold Fibrosis: The Role of Serum Biomarkers to assess the Immune Mechanisms and ECM-Cell Interactions in Human Fibrosis DOI Creative Commons
Andressa de Zawadzki, Diana Julie Leeming, Arun J. Sanyal

и другие.

Journal of Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Fibrosis is a pathological condition characterized by excessive accumulation of extracellular matrix (ECM) components, particularly collagens, leading to tissue scarring and organ dysfunction. In fibrosis, an imbalance between collagen synthesis (fibrogenesis) degradation (fibrolysis) results in the deposition fibrillar collagens disrupting structural integrity ECM and, consequently, architecture. associated with wide range chronic diseases, including liver cirrhosis, kidney pulmonary autoimmune diseases. Recently, concept "hot" "cold" fibrosis has emerged, referring immune status within fibrotic tissues nature fibrogenic signaling. Hot active cell infiltration inflammation, while cold auto- paracrine myofibroblast activation, exclusion quiescence. This article aims explore relationship hot role various types their biologically fragments modulating system, how serological biomarkers can help understanding disease-relevant interactions mesenchymal cells tissues. Additionally, we draw lessons from immuno-oncology research solid tumors shed light on potential strategies for treatment highlight advantage having "hot environment" treat enhancing through modulation system.

Язык: Английский

Процитировано

1
Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis? DOI Open Access
Aneta Sokal, Sara Jarmakiewicz-Czaja, Katarzyna Ferenc

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(10), С. 5238 - 5238

Опубликована: Май 11, 2024

Currently, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are considered to be the main causes of fibrosis. In turn, fibrosis may lead development hepatocellular carcinoma or advanced cirrhosis, i.e., potentially life-threatening conditions. It is likely that therapy aimed at reducing risk developing hepatic steatosis inflammation could helpful in minimizing threat/probability organ recent years, increasing attention has been paid influence nutraceuticals prevention treatment diseases. Therefore, aim this review was describe precise role selected ingredients such as vitamin C, beta-carotene, omega-3 fatty acids, curcumin. use these patients with MASLD/MASH, along behavioral pharmacological therapy, have a beneficial effect on combating inflammation, oxidative stress, thereby preventing damage.

Язык: Английский

Процитировано

7
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment DOI Creative Commons
Yanju Liu, Hongyuan Yang, Tian Li

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Сен. 3, 2024

Liver cancer is a major global health concern, ranking among the top causes of cancer-related deaths worldwide. Despite advances in medical research, prognosis for liver remains poor, largely due to inherent limitations current therapies. Traditional treatments like surgery, radiation, and chemotherapy often fail provide long-term remission are associated with significant side effects. Immunotherapy has emerged as promising avenue treatment, leveraging body's immune system target destroy cells. However, its application been limited. One primary challenges liver's unique microenvironment, which can inhibit effectiveness immunotherapeutic agents. This microenvironment creates barrier, leading drug resistance reducing overall efficacy treatment. Recent studies have focused on understanding immunological landscape develop strategies that overcome these obstacles. By identifying specific factors within contribute suppression resistance, researchers aim enhance immunotherapy. Prospective include combining immunotherapy other treatments, using targeted therapies modulate developing new agents bypass or counteract inhibitory mechanisms liver. These advancements hold promise improving outcomes

Язык: Английский

Процитировано

5
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches DOI Open Access
Shabnam Eghbali, Thatcher Heumann

Cancers, Год журнала: 2025, Номер 17(2), С. 236 - 236

Опубликована: Янв. 13, 2025

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and, with only 15-20% HCC patients being suitable for potentially curative treatments, the vast majority ultimately require systemic therapy. For decades, choice effective therapy remained sparse. In recent years, after combination atezolizumab and bevacizumab demonstrated superior overall survival over first-line standard, sorafenib, there has been major therapeutic paradigm shift to immunotherapy-based regimens HCC. While representing great leap forward treatment this cancer, reality that less than one-third achieve an objective response immune checkpoint inhibitor-based therapy, so remains significant clinical need further optimization. review, we provide overview current landscape immunotherapy unresectable delve into tumor intrinsic extrinsic mechanisms resistance established immunotherapies focus on novel targets strong translational potential. Following this, spotlight emerging approaches notable trials aiming optimize efficacy in include inhibitors, microenvironment modulators, targeted delivery systems, locoregional interventions.

Язык: Английский

Процитировано

0
Metabolic Crosstalk between Platelets and Cancer: Mechanisms, Functions, and Therapeutic Potential DOI
Zhixue Chen, Xu Lin, Yuan Yu

и другие.

Seminars in Cancer Biology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics DOI Open Access
M.A. Karsdal, Thomas R. Cox, Amelia L. Parker

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(6), С. 1856 - 1856

Опубликована: Март 10, 2025

The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some these pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased degradation, some exhibit a combination both, leading severe alterations. To develop effective therapies for diseases affecting lung, liver, kidney, skin, intestine, musculoskeletal system, heart, solid tumors, we need modulate ECM’s composition restore its organization function. Across diverse organ diseases, there denominators distinguishing factors in this fibroinflammatory axis, which may be used foster new insights into drug development across disease indications. 2nd Extracellular Matrix Pharmacology Congress took place Copenhagen, Denmark, from 17 19 June 2024 was hosted by International Society Pharmacology. event attended 450 participants 35 countries, among whom were prominent scientists who brought together state-of-the-art research on asked important questions facilitate development. We highlight key aspects ECM lungs, tumors advance our understanding central targets also advances tools technology that enable development, thereby supporting ECM.

Язык: Английский

Процитировано

0
Ultrasound‐Mediated Biomimetic Microbubbles Effectively Reverse LSECs Capillarization and Exert Antiplatelet Therapy in Liver Fibrosis DOI
Huan Deng,

Huolin Ye,

Hong Xiao

и другие.

Advanced Healthcare Materials, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

Abstract Liver fibrosis, characterized by excessive tissue remodeling as a response to chronic liver injury, is accompanied capillarization of sinusoidal endothelial cells (LSECs) and activated hepatic stellate (HSCs). Simvastatin (Sim) can modulate function increasing nitric oxide synthase (eNOS)‐dependent (NO) release, thereby reversing attenuating fibrosis. However, monotherapy often demonstrates limited therapeutic effectiveness given the complex pathophysiology Herein, type multifunctional liposomal microbubbles (MBs) carrying both Sim platelet membrane (PM) has been designed for drug delivery targeting inflammatory LSECs, with ultrasound‐targeted microbubble destruction (UTMD) mediate efficient release these agents inside sinusoidal. In rat fibrosis model, MBs reverses through increase eNOS‐dependent NO production. Subsequently, adhering LSECs block adhesion activation inherent (PLT), decreasing platelet‐derived growth factor β (PDGF‐β) inhibit HSCs activation. This study strong efficacy integrating PLT against which highlights great potential effectively managing this intractable disease.

Язык: Английский

Процитировано

0
Tumor cell-derived osteopontin promotes tumor fibrosis indirectly via tumor-associated macrophages DOI Creative Commons

Yuying Tan,

Yong‐Guang Yang,

Xiaoying Zhang

и другие.

Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Апрель 11, 2025

Язык: Английский

Процитировано

0
Nets in fibrosis: Bridging innate immunity and tissue remodeling DOI
Xueni Ma,

LI Ji-pin,

Muyang Li

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 137, С. 112516 - 112516

Опубликована: Июнь 20, 2024

Язык: Английский

Процитировано

3
Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy DOI Creative Commons

Yingxin Tian,

Yiming Ni, Ting Zhang

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12

Опубликована: Сен. 5, 2024

Non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH), have become global health challenges with significant morbidity mortality rates. NAFLD encompasses several diseases, ranging from simple steatosis to severe inflammatory fibrotic forms. Ultimately, this can lead cirrhosis hepatocellular carcinoma. The intricate role of hepatic macrophages, particularly Kupffer cells (KCs) monocyte-derived macrophages (MoMFs), in the pathogenesis NASH, has received increasing attention. Hepatic interact hepatocytes, stellate cells, endothelial playing a crucial maintaining homeostasis. Paradoxically, they also participate some diseases. This review highlights fundamental emphasizing their plasticity contribution inflammation fibrosis, hopes provide ideas for subsequent experimental research clinical treatment.

Язык: Английский

Процитировано

3